The ATM gene provides the blueprint for a large protein kinase that serves as one of the body’s most important molecular alarm systems, detecting broken DNA and orchestrating the cellular response to repair it. Identified in 1995 through positional cloning on chromosome 11, the gene takes its name from ataxia-telangiectasia (A-T), the severe childhood disorder that results when both copies are knocked out. But ATM’s relevance extends well beyond that rare disease. People who carry a single faulty copy, estimated at roughly 0.5 to 2 percent of the population, face moderately elevated risks of breast, pancreatic, and prostate cancer, and the gene has become a focus of precision oncology, genetic counseling, and experimental therapies.
What the ATM Protein Actually Does
ATM is best known as a guardian of the genome. When both strands of a DNA molecule break, a sensor complex called MRN (Mre11-Rad50-Nbs1) detects the damage and physically recruits ATM to the break site. ATM normally sits as an inactive dimer, but MRN’s unwinding of the broken DNA ends triggers it to split into active single molecules. Once switched on, ATM phosphorylates a cascade of downstream targets, including the tumor-suppressor protein p53 and the checkpoint kinase Chk2, which together halt the cell cycle and either coordinate repair or push a badly damaged cell toward self-destruction.1PubMed. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex2PubMed. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
That DNA-repair role is only part of the story. ATM can also be activated directly by reactive oxygen species (ROS), the chemically aggressive byproducts of normal metabolism, without any DNA breakage at all. When cellular ROS levels climb, ATM works in the cytoplasm rather than the nucleus, activating the tumor suppressor TSC2 through a metabolic signaling chain that ultimately dials down cell growth and triggers autophagy, the process by which cells recycle their own damaged components.3PubMed Central. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS This dual identity as both a DNA-damage responder and a redox sensor helps explain why losing ATM affects so many different tissues and organ systems.4PubMed Central. ATM at the crossroads of reactive oxygen species and autophagy
Ataxia-Telangiectasia, the Disease That Named the Gene
When a child inherits a disabling mutation in both copies of ATM, the result is A-T, a rare autosomal recessive disorder that affects roughly one in 40,000 to 100,000 live births worldwide. Neurological symptoms usually appear first, often when a toddler begins to walk. The hallmark is progressive cerebellar degeneration, which causes worsening coordination, slurred speech, and involuntary eye movements. Small clusters of dilated blood vessels called telangiectasias typically show up on the whites of the eyes and on sun-exposed skin, giving the disease its other name feature.5PubMed Central. Ataxia telangiectasia: a review
Beyond the nervous system, children with A-T usually have immune deficiencies, including low levels of certain antibodies and reduced lymphocyte counts, making them vulnerable to recurrent sinus and lung infections. Over time, those infections contribute to bronchiectasis, airway scarring, and progressive lung disease, which together with cancer are the leading causes of death.6PubMed. Lung disease in ataxia-telangiectasia Children with A-T also have a dramatically elevated susceptibility to cancers of lymphoid origin, and they are extremely sensitive to ionizing radiation, which complicates both cancer treatment and even routine diagnostic imaging.7PubMed Central. Ataxia telangiectasia: a review
The severity of A-T varies considerably from person to person. Some individuals retain a small amount of functional ATM protein and have a milder course, sometimes called “variant A-T,” while those with no residual protein tend to have earlier onset and faster progression. This variability makes diagnosis tricky and partly explains why there is still no approved disease-modifying therapy.
Why the Cerebellum Is So Vulnerable
One of the most puzzling aspects of A-T is its selectivity. ATM is expressed in cells throughout the body, yet the neurons that degenerate earliest and most severely are the Purkinje cells of the cerebellum, the large neurons responsible for fine-tuning movement. Research using a macaque model of A-T has reproduced this specificity, showing cerebellar atrophy, Purkinje cell loss, and motor impairments closely resembling the human disease. Gene-expression profiling of these macaque cerebellums identified pronounced changes in a type of neuron called molecular layer interneurons, which normally help regulate Purkinje cell activity, suggesting that the damage starts at least partly through disrupted circuits rather than simple cell-autonomous failure.8PubMed Central. ATM deficiency drives phenotypic diversity and Purkinje cell degeneration in a macaque model of ataxia-telangiectasia
Human brain tissue studies tell a complementary story. Single-nucleus transcriptomic work on A-T cerebellar tissue has shown that microglia, the brain’s resident immune cells, become activated and begin producing inflammatory signals before Purkinje cells and granule neurons start dying. In other words, an inflammatory process appears to precede and drive neurodegeneration, rather than simply following it.9Cell Reports. Microglial activation promotes cerebellar degeneration in ataxia-telangiectasia
There is also an epigenetic angle. A chemical mark on DNA called 5-hydroxymethylcytosine (5hmC), which is especially abundant in neurons and involved in gene regulation, is substantially reduced in A-T Purkinje cells. The enzyme responsible for producing 5hmC, TET1, turns out to respond to DNA damage, and manipulating its activity in mouse models directly affects whether Purkinje cells re-enter the cell cycle and die. Restoring 5hmC levels partially rescues the degenerative process, pointing to an epigenetic vulnerability that is specific to these neurons.10Brain. Alteration in 5-hydroxymethylcytosine-mediated epigenetic regulation leads to Purkinje cell vulnerability in ATM deficiency
Cancer Risks for Carriers of a Single ATM Mutation
Full-blown A-T is rare, but carrying one working and one faulty copy of ATM is far more common and carries its own medical implications. The American College of Medical Genetics and Genomics recognizes pathogenic ATM variants as conferring a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer.11PubMed. Management of individuals with heterozygous germline pathogenic variants in ATM
Breast Cancer
Women with one pathogenic ATM variant face a lifetime breast cancer risk of roughly 25 percent, and most of those cancers are estrogen-receptor-positive.12PubMed Central. Breast cancer and ATM mutations: treatment implications A large study tracking families of A-T patients found that the overall relative risk of breast cancer for carriers was about two-fold compared to the general population, but for carriers younger than 50 it jumped to nearly five-fold.13JNCI: Journal of the National Cancer Institute. Cancer Risks and Mortality in Heterozygous ATM Mutation Carriers That age gradient matters for screening decisions. Many guidelines now recommend enhanced breast cancer surveillance, often including annual MRI starting earlier than the general population would get one, for women who carry pathogenic ATM variants.
Pancreatic Cancer
Pancreatic cancer is uncommon overall, but ATM carriers face a relative risk roughly six and a half times that of non-carriers. The cumulative risk reaches about 6 percent by age 70 and around 9.5 percent by age 80.14JAMA Oncology. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene ATM mutations have also been identified at elevated rates in families with a strong history of pancreatic cancer, and sequencing studies have confirmed that deleterious ATM variants are significantly more common in familial pancreatic cancer patients than in unrelated controls.15PubMed Central. ATM mutations in hereditary pancreatic cancer patients These findings have made ATM one of the genes included in multigene panel tests offered to people with a family history of pancreatic cancer.
Prostate Cancer
The link to prostate cancer has become clearer in recent years. Carriers of pathogenic ATM variants appear to develop more aggressive tumors. In one study, high-grade prostate tumors (Gleason score 8–10) were found in 56 percent of men carrying mutations in ATM, BRCA2, or a related gene called NBN, compared with 21 percent of men without those mutations.16PubMed. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland Another analysis found that ATM and BRCA2 pathogenic variant carriers were disproportionately represented among men with aggressive disease versus non-aggressive disease.17PubMed. Rare germline genetic variants and risk of aggressive prostate cancer Guidelines increasingly recommend that men with known ATM mutations discuss earlier or more intensive prostate-cancer screening with their doctors.
Blood Cancers
ATM also plays a role in cancers of the blood. Somatic ATM mutations, meaning mutations that arise in blood cells during a person’s life rather than being inherited, have been found in a fraction of B-cell chronic lymphocytic leukemias (B-CLL). In some cases, one ATM allele is deleted while the remaining copy carries a disabling point mutation, effectively eliminating ATM function in the tumor.18Blood. Somatic ATM Mutations Indicate a Pathogenic Role of ATM in B-Cell Chronic Lymphocytic Leukemia There is also evidence that germline ATM mutations may predispose some individuals to B-CLL.19PubMed. ATM mutations in B-cell chronic lymphocytic leukemia
ATM, Metabolism, and Insulin Resistance
If you think of ATM purely as a cancer gene, the metabolic connection comes as a surprise. In mouse models, having just one working copy of ATM alongside a high-fat diet is enough to produce three hallmarks of metabolic syndrome: increased body fat, elevated blood pressure, and glucose intolerance. The underlying mechanism involves hepatic insulin resistance: the liver stops responding properly to insulin’s signal to suppress glucose production. At the molecular level, key insulin-signaling molecules are less active in the livers of ATM-deficient mice.20Cell Metabolism. ATM Signaling Mediates the Metabolic Syndrome Human studies have associated ATM deficiency with the development of insulin resistance and diabetes, consistent with the animal data.21PubMed Central. Heart failure and diabetes: role of ATM
This metabolic role likely reflects ATM’s function as a redox sensor. Metabolic overload generates excess ROS, and if ATM isn’t there to sense that oxidative stress and activate protective pathways like autophagy, cells accumulate damage faster. It’s a reminder that genes rarely do just one thing, and categorizing ATM as a “DNA repair gene” understates its reach.
ATM and Cellular Aging
ATM sits at a crossroads of cellular senescence, the process by which cells permanently stop dividing in response to accumulated damage. When DNA double-strand breaks persist over time, ATM drives the activation of a pro-inflammatory program known as the senescence-associated secretory phenotype (SASP), partly through the transcription factor NF-κB. In experimental models, inhibiting ATM reduced markers of senescence, SASP output, and downstream effects like stem cell dysfunction, suggesting ATM is not just a passive participant but a major driver of cellular aging processes.22PubMed Central. ATM is a key driver of NF-κB-dependent DNA-damage-induced senescence, stem cell dysfunction and aging
The timing of SASP activation involves an interesting wrinkle. After DNA damage, the immediate ATM response involves conventional kinase signaling. But the full inflammatory secretory program takes days to develop and depends on a delayed, non-canonical accumulation of ATM on chromatin that does not even require its kinase activity, hinting at a structural scaffolding role.23PubMed Central. Non-canonical ATM/MRN activities temporally define the senescence secretory program This dual function means ATM is simultaneously protective (repairing acute damage) and pro-aging (promoting chronic inflammation when damage persists). That paradox is one reason researchers have explored ATM as a potential therapeutic target in age-related diseases, though such work remains preclinical.
Precision Oncology and ATM-Deficient Tumors
The same DNA-repair deficiency that makes A-T patients sensitive to radiation also creates therapeutic vulnerabilities in tumors that have lost ATM. The concept of synthetic lethality, where disabling a second repair pathway kills cells that have already lost ATM, has driven interest in using PARP inhibitors against ATM-deficient cancers. PARP inhibitors have already transformed treatment for BRCA-mutated cancers, and ATM loss similarly impairs homologous recombination repair. However, the story is more nuanced than a simple copy-paste from BRCA biology. Research has shown that PARP inhibition alone tends to be cytostatic (stopping growth) but not cytotoxic (killing) in ATM-deficient cancer cells, and that combining a PARP inhibitor with an inhibitor of the related kinase ATR is needed to actually push those cells toward death.24PubMed Central. ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Preclinical work using patient-derived tumor models has reinforced the potential. In lung cancer models harboring biallelic ATM mutations, the PARP inhibitor niraparib caused significant tumor regression in about a third of the cases tested. Those sensitive tumors also showed reduced levels of BRCA1 and BRCA2 proteins, suggesting that ATM loss may drag down other repair machinery too, compounding the vulnerability.25PubMed Central. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation
On the radiation therapy side, small-molecule ATM inhibitors are being tested as radiosensitizers. The idea is to temporarily block ATM in tumor cells during radiation treatment, making the radiation more lethal to the cancer while sparing normal tissue. One ATM inhibitor, AZD0156, showed a clear radiosensitizing effect in melanoma cells but not in healthy fibroblasts, a promising sign for therapeutic selectivity.26PubMed Central. Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts
The Problem of Variants of Uncertain Significance
Genetic testing for ATM mutations has become routine in multigene cancer panels, but the results are not always straightforward. ATM is a large gene with many possible variants, and a substantial fraction of detected changes are classified as variants of uncertain significance (VUS), meaning it is unclear whether they actually increase risk. This ambiguity creates real clinical headaches. A VUS cannot be used to guide screening or surgical decisions, and it can cause significant anxiety for patients who learn they carry one.
Collaborative efforts to improve classification have made headway. A dedicated expert panel created ATM-specific rules for evaluating variant pathogenicity, building on the general ACMG/AMP guidelines. In one pilot study, applying these refined criteria and sharing data among clinical laboratories reduced the VUS rate from 58 percent to 42 percent and identified 27 carriers of clearly pathogenic or likely pathogenic variants, findings that directly changed clinical management for those individuals and their relatives.27Clinical Chemistry. A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients A larger curation effort achieved an 85 percent classification rate across a set of test variants, resolving several that had conflicting interpretations in public databases.28The American Journal of Human Genetics. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants Still, VUS remain common, and the advice for anyone who receives a VUS result is to follow up with a genetic counselor and check back periodically, because reclassification happens as databases grow.
One area where variant interpretation matters acutely is radiation therapy. Patients with A-T are known to be exquisitely radiation-sensitive, and there is concern that even heterozygous carriers could have heightened toxicity. But clinical data on carriers is mixed. In a small series, a patient with a clearly pathogenic ATM mutation showed no unusual radiation toxicity, while one of four patients with VUS-classified ATM variants developed grade 3 skin reactions.29PubMed Central. Increased radiation toxicity with germline ATM variant of uncertain clinical significance That kind of unpredictability is exactly why better variant classification is so urgently needed.
Experimental Treatments for A-T
There is currently no approved therapy that halts or reverses the neurodegeneration of A-T, but a few approaches are generating cautious optimism. The most advanced genetic strategy involves antisense oligonucleotides (ASOs), short synthetic strands of nucleic acid that can correct specific splicing errors at the RNA level. Since many A-T-causing mutations disrupt normal splicing of the ATM gene, an ASO targeted to the aberrant splice site can restore production of full-length, functional ATM protein. This has been demonstrated in patient-derived cell lines, where ASO treatment both restored ATM and reduced the cells’ sensitivity to radiation damage.30PubMed Central. Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome
Getting ASOs into the brain is the major hurdle. Researchers have shown that attaching cell-penetrating peptides to ASOs and injecting them intravenously in mice allows efficient uptake in the brain, including the cerebellum, with detectable ATM protein still present three weeks after a single dose. Based on this preclinical work, a personalized intrathecal ASO called Atipeksen was developed for a young child with A-T. That trial is ongoing and too early to judge, but the approach follows a path already validated in spinal muscular atrophy, where a similar ASO strategy became standard treatment.31PubMed Central. Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome
Other ASO work has targeted a naturally occurring regulatory mechanism in the ATM gene itself: a nonsense-mediated decay switch exon whose inclusion or exclusion in the final RNA product affects how much ATM protein a cell makes. By tuning this switch, researchers have been able to either boost or suppress ATM expression, the latter potentially useful as a way to radiosensitize tumor cells without drugs.32PubMed Central. Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene
ATM Across the Tree of Life
ATM is not unique to humans. The gene is conserved across essentially all eukaryotic organisms, from fruit flies to rice plants, underscoring how fundamental the DNA double-strand break response is to life. In Drosophila, ATM-related kinases carry out the same core functions: promoting repair of broken DNA and maintaining chromosome stability, including telomere integrity.33PubMed. Molecular genetic characterization of Drosophila ATM conserved functional domains
Plants have their own versions with some interesting twists. The ATM protein is structurally conserved at the protein level across plant species, but plant ATM genes also carry domains not found in their animal counterparts, such as PWWP domains and coiled-coil regions, suggesting plant-specific evolutionary adaptations. The functional consequences of losing ATM also vary dramatically between plant species: Arabidopsis mutants show partial sterility, rice mutants are completely sterile, and maize mutants have normal fertility. These differences likely reflect the varying genome sizes and complexities of these species and illustrate how a deeply conserved gene can be repurposed in different lineages.34Plant Stress. ATM kinase in plants: Integrating DNA damage response, development, and stress adaptation
The evolutionary depth of ATM conservation also informs medical research. The macaque model of A-T mentioned earlier was specifically sought out because mouse models of the disease have never fully recapitulated the cerebellar neurodegeneration seen in humans. Mice with ATM knocked out develop cancer and immune deficiency but show only subtle neurological changes, a frustrating gap that has slowed therapeutic development for decades. The fact that non-human primates more faithfully reproduce the human neurological phenotype suggests that some aspects of ATM’s role in the brain may have evolved or intensified in the primate lineage, making these models especially valuable for testing future treatments.35PubMed Central. ATM deficiency drives phenotypic diversity and Purkinje cell degeneration in a macaque model of ataxia-telangiectasia